India's Zydus Life gains on deal to launch hypertension drug in US
BUZZ-India's Zydus Life gains on deal to launch hypertension drug in US ** Drug maker Zydus Lifesciences ZYDU.NS shares rise as much as 2.27% to 1,164.80 rupees apiece
** Rise after ZYDU announces partnership with MSN Laboratories and launches Riociguat tablets in the US
** ZYDU and MSN are the first companies to launch generic Riociguat, a drug indicated for the treatment of adults with persistent or recurrent chronic thromboembolic pulmonary hypertension
** According to drugmaker Bayer's annual report 2025, global sales of Adempas (the brand name of riociguat) were approximately $850 million in 2025
** ZYDU shares are up about 27% in 2026 so far, outperforming the 16.4% rise in the pharma index .NIPHARM, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka